Shire Enhances its Orphan Drug Pipeline With the Acquisition of a … - PR Newswire (press release)
|
Shire Enhances its Orphan Drug Pipeline With the Acquisition of a …
PR Newswire (press release), NY - Apr 23, 2008 … but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")) … Shire pays $135 million to Zymenex for MLD drug Pharma Times (subscription) all 27 news articles |
Find Out More:
Books:
- Ritalin Is Not The Answer: A Drug-Free, Practical Program for Children Diagnosed with ADD or ADHD
- The Attention Deficit Answer Book: The Best Medications and Parenting Strategies for Your Child
- ADHD: Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults
- Stopping ADHD
- The Million Dollar Shot
April 26th, 2008
Vyvanse
Leave a Reply